OTCMKTS:ALSE

Alseres Pharmaceuticals Competitors

$6.00
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.00
Now: $6.00
$6.00
50-Day Range
$6.00
MA: $6.00
$6.00
52-Week Range
$6.00
Now: $6.00
$6.00
VolumeN/A
Average Volume100 shs
Market Capitalization$36,000.00
P/E RatioN/A
Dividend YieldN/A
Beta-0.06

Competitors

Alseres Pharmaceuticals (OTCMKTS:ALSE) Vs. ROSGQ, MTST, OREXQ, AXMP, BOPH, and IMUN

Should you be buying ALSE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Alseres Pharmaceuticals, including Rosetta Genomics (ROSGQ), MetaStat (MTST), Orexigen Therapeutics (OREXQ), AXM Pharma (AXMP), Bohai Pharmaceuticals Group (BOPH), and Immune Therapeutics (IMUN).

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Rosetta Genomics (OTCMKTS:ROSGQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Alseres Pharmaceuticals and Rosetta Genomics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alseres PharmaceuticalsN/AN/AN/AN/AN/A
Rosetta GenomicsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Alseres Pharmaceuticals and Rosetta Genomics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alseres Pharmaceuticals0000N/A
Rosetta Genomics0000N/A

Volatility and Risk

Alseres Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Rosetta Genomics has a beta of 6.39, indicating that its share price is 539% more volatile than the S&P 500.

Profitability

This table compares Alseres Pharmaceuticals and Rosetta Genomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alseres PharmaceuticalsN/AN/AN/A
Rosetta GenomicsN/AN/AN/A

Summary

Rosetta Genomics beats Alseres Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Alseres Pharmaceuticals (OTCMKTS:ALSE) and MetaStat (OTCMKTS:MTST) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Alseres Pharmaceuticals and MetaStat's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alseres PharmaceuticalsN/AN/AN/AN/AN/A
MetaStat$20,000.005.88$-3,180,000.00N/AN/A

Alseres Pharmaceuticals has higher earnings, but lower revenue than MetaStat.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Alseres Pharmaceuticals and MetaStat, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alseres Pharmaceuticals0000N/A
MetaStat0000N/A

Volatility and Risk

Alseres Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, MetaStat has a beta of -4.21, indicating that its share price is 521% less volatile than the S&P 500.

Profitability

This table compares Alseres Pharmaceuticals and MetaStat's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alseres PharmaceuticalsN/AN/AN/A
MetaStatN/AN/AN/A

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Orexigen Therapeutics (OTCMKTS:OREXQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Alseres Pharmaceuticals and Orexigen Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alseres PharmaceuticalsN/AN/AN/AN/AN/A
Orexigen Therapeutics$33.71 million0.00$-24,520,000.00N/AN/A

Alseres Pharmaceuticals has higher earnings, but lower revenue than Orexigen Therapeutics.

Volatility and Risk

Alseres Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Orexigen Therapeutics has a beta of 4.98, indicating that its share price is 398% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Alseres Pharmaceuticals and Orexigen Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alseres Pharmaceuticals0000N/A
Orexigen Therapeutics0000N/A

Profitability

This table compares Alseres Pharmaceuticals and Orexigen Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alseres PharmaceuticalsN/AN/AN/A
Orexigen TherapeuticsN/AN/AN/A

Summary

Orexigen Therapeutics beats Alseres Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Alseres Pharmaceuticals (OTCMKTS:ALSE) and AXM Pharma (OTCMKTS:AXMP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Alseres Pharmaceuticals and AXM Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alseres PharmaceuticalsN/AN/AN/AN/AN/A
AXM PharmaN/AN/AN/AN/AN/A

Volatility & Risk

Alseres Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, AXM Pharma has a beta of -52.62, indicating that its share price is 5,362% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Alseres Pharmaceuticals and AXM Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alseres Pharmaceuticals0000N/A
AXM Pharma0000N/A

Profitability

This table compares Alseres Pharmaceuticals and AXM Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alseres PharmaceuticalsN/AN/AN/A
AXM PharmaN/AN/AN/A

Summary

Alseres Pharmaceuticals beats AXM Pharma on 1 of the 1 factors compared between the two stocks.

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Bohai Pharmaceuticals Group (OTCMKTS:BOPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Alseres Pharmaceuticals and Bohai Pharmaceuticals Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alseres PharmaceuticalsN/AN/AN/AN/AN/A
Bohai Pharmaceuticals GroupN/AN/AN/AN/AN/A

Volatility & Risk

Alseres Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Bohai Pharmaceuticals Group has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Alseres Pharmaceuticals and Bohai Pharmaceuticals Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alseres Pharmaceuticals0000N/A
Bohai Pharmaceuticals Group0000N/A

Profitability

This table compares Alseres Pharmaceuticals and Bohai Pharmaceuticals Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alseres PharmaceuticalsN/AN/AN/A
Bohai Pharmaceuticals GroupN/AN/AN/A

Summary

Bohai Pharmaceuticals Group beats Alseres Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Immune Therapeutics (OTCMKTS:IMUN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Alseres Pharmaceuticals and Immune Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alseres PharmaceuticalsN/AN/AN/AN/AN/A
Immune Therapeutics$110,000.000.08$-3,400,000.00N/AN/A

Alseres Pharmaceuticals has higher earnings, but lower revenue than Immune Therapeutics.

Volatility & Risk

Alseres Pharmaceuticals has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Immune Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Institutional & Insider Ownership

7.7% of Immune Therapeutics shares are owned by institutional investors. 8.9% of Alseres Pharmaceuticals shares are owned by insiders. Comparatively, 11.7% of Immune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Alseres Pharmaceuticals and Immune Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alseres Pharmaceuticals0000N/A
Immune Therapeutics0000N/A

Profitability

This table compares Alseres Pharmaceuticals and Immune Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alseres PharmaceuticalsN/AN/AN/A
Immune TherapeuticsN/A-11.54%7,012.86%

Summary

Immune Therapeutics beats Alseres Pharmaceuticals on 5 of the 6 factors compared between the two stocks.


Alseres Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ROSGQ
Rosetta Genomics
0.0$0.09flat$124,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.02flat$118,000.00$20,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00flat$81,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02flat$9,000.00$110,000.000.00Decrease in Short Interest
Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.03flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.09flat$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50flat$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00Gap Up
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49flat$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$35.36flat$0.00N/A0.00Decrease in Short Interest
News Coverage
Gap Down
HRBR
Harbor Diversified
0.0$1.16flat$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00Gap Up
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Up
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00Decrease in Short Interest
News Coverage
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.07flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.03flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.07flat$0.00$26.09 million0.00High Trading Volume
Increase in Short Interest
News Coverage
Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Increase in Short Interest
News Coverage
Gap Down
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00Gap Down
Targeted Medical Pharma logo
TRGM
Targeted Medical Pharma
0.8$0.07flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.02flat$0.00N/A0.00
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.